Connect with us

News

Medical cannabis and cancer research gets $1.5 million boost

An Australian study will explore the use of medical cannabis to prevent side effects of cancer treatment.

Published

on

Cancer treatment
The University of Adelaide will study how medical cannabis could be used to prevent side effects of cancer treatment

A new Australian study will explore the use of medical cannabis to prevent side effects of ‘toxic’ cancer treatment.

The University of Adelaide has been awarded Government funding of $1.5 million to study how the use of personalised medicinal cannabis dosing could prevent common and impactful symptoms of advanced cancer treatment. 

The Medical Research Future Fund investment was awarded to Dr Hannah Wardill for the Cancan trial – a large clinical study which aims to guide clinical practice.

“Cancer therapies are highly toxic and cause a constellation of physical and psychosocial symptoms that negatively impact quality of life, dose intensity and survival,” Dr Wardill said.

“Recent attention has centred on the use of medicinal cannabis for the management of these symptoms. While largely driven by patients and their advocates, the use of cannabis in this context has challenged medical professionals who feel ill-equipped to guide their patients due to the lack of empirical evidence.

“The Cancan trial will show that targeting gut distress, due to mucosal injury, with medical cannabis will improve patient wellbeing and maintenance of intended dosing.”

Dr Wardill also hopes that the personalised CBD and THC preparation will “prevent and manage clusters of related side effects of cancer therapy” including detrimental effects to sleep, appetite, mood, pain and fatigue.

Professor Anton Middelberg, deputy vice-chancellor says the University of Adelaide has a strategic commitment to tackling the grand challenge of improving health and wellbeing for all society.

He commented: “This funding announcement allows our researchers to deliver on our health priority and to potentially improve the quality of life of those undergoing cancer treatment,” Professor Middelberg said.

Sarah Sinclair is an award-winning freelance journalist covering health, drug policy and social affairs. She is one of the few UK reporters specialising in medical cannabis policy and as the former editor of Cannabis Health has covered developments in the European cannabis sector extensively, with a focus on patients and consumers. She continues to report on cannabis-related health and policy for Forbes, Cannabis Health and Business of Cannabis and has written for The i Paper, Byline Times, The Lead, Positive News, Leafie & others. Sarah has an NCTJ accreditation and an MA in Journalism from the University of Sunderland and has completed additional specialist training through the Medical Cannabis Clinicians Society in the UK. She has spoken at leading industry events such as Cannabis Europa.

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.